PPIDT00490

Drug Information
NameAmivantamab
SequenceNot Available
DrugBank_IDDB16695
Typebiotech
IndicationAmivantamab is indicated for the following conditions: - in combination with [lazertinib], it is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.[L51179] - in combination with [carboplatin] and [pemetrexed] for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test.[L51174,L51179] - indicated as a single agent for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.[L34193,L41469,L41479,L43842,L51174,L51179]
Dosage Forms
Form Route Strength
Injection Intravenous
350 mg/1
Injection, solution, concentrate Intravenous
350 mg
Solution Intravenous
350 mg / 7 mL
Solution Intravenous
350.00 mg
Injection, solution, concentrate Intravenous
350 mg/7mL
Target Information
Role Uniprot_ID Gene_Name Entity_Name Organism Actions Internal link
target P00533 EGFR Epidermal growth factor receptor Homo sapiens antibody|downregulator Link
target P08581 MET Hepatocyte growth factor receptor Homo sapiens antagonist|antibody Link
target P08637 FCGR3A Low affinity immunoglobulin gamma Fc region receptor III-A Homo sapiens inducer Link